Concomitant loss of CD166 and CD44s molecules was observed in 276 tumours, whereas the remaining 884 cases displayed various combinations of these two markers including 275 CD166+/CD44s− cases, 180 CD166−/CD44s+ cases, and 429 double-positive cases. Here, ALCAM is linked to neoplasm.